NEW YORK – BioNTech said Wednesday that it began an exchange offer to complete its $1.25B all-stock acquisition of mRNA immunotherapy developer CureVac, a deal that was announced in June.

Novavax is slimming down again by striking a deal to transfer the lease to its Maryland corporate headquarters to AstraZeneca in exchange for nearly $60 million. | Novavax will remain headquartered at ...

Novavax, Inc.  today announced that it has further executed against its planned transformation into a lean, agile operating model by signing definitive agreements related to one of its Maryland-based ...

Under FDA regulations, suspension is not the end of the process. Unless a license holder voluntarily relinquishes its license ...

The head of the NC Pharmacy Board explains what it takes after all the federal guideline shifts to get a vaccine from your ...

Himanshu Shah, managing partner and chief investment officer at Shah Capital, slammed management, and said the company should ...

Shah Capital urges Novavax to consider a sale after poor COVID-19 vaccine rollout, highlighting the potential value of at ...

AstraZeneca followed the blueprint of a deal Pfizer recently cut with the White House. Elsewhere, Novo is shuttering its cell ...

Experts emphasize that there has been no real change in the benefits or risks of the vaccines, which are quite safe and offer ...

So why did I volunteer to be injected with an experimental vaccine for COVID-19? That's what some of my friends wanted to know when I told them what I was doing.

Novavax Inc said on Monday it was on track to begin a delayed U.S.-based, late-stage study of its experimental coronavirus vaccine later this month.